Our previous studies demonstrated that different restricted combinations in early stage ESCC and nasopharyngeal carcinoma, autoantibodies against p53, NY-ESO-1, PRDX6 and Hsp70, and autoantibodies against p53, NY-ESO-1, Bmi-1 and Hsp70, respectively, kept high sensitivity and specificity in detecting corresponding tumor samples [13, 14]. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.